Curis Lifesciences FY26 net profit rises 11.4% to ₹691.63 lakh
Curis Lifesciences reported an 11.4% rise in FY26 net profit to ₹691.63 lakh, driven by a 20.6% increase in revenue to ₹6062.88 lakh. The Board approved the audited standalone financial results for the year ended March 31, 2026. The company also announced a strategic investment in Uninova Lifesciences Private Limited.
*this image is generated using AI for illustrative purposes only.
Curis Lifesciences reported an 11.4% increase in net profit to ₹691.63 lakh for the year ended March 31, 2026, compared to ₹620.64 lakh in the previous year. Revenue from operations rose 20.6% to ₹6062.88 lakh from ₹5025.86 lakh in FY25. The Board of Directors approved the audited standalone financial results for the half year and year ended March 31, 2026, at a meeting held on May 30, 2026.
The company’s total income for FY26 stood at ₹6091.04 lakh, up from ₹5027.08 lakh in the previous year. Total expenses increased to ₹5133.41 lakh from ₹4129.52 lakh. Profit before tax for the year was ₹956.16 lakh, compared to ₹898.80 lakh in the prior year. For the half year ended March 31, 2026, net profit was ₹270.55 lakh on revenue of ₹3271.99 lakh.
Financial Performance
The earnings per share (EPS) for the year ended March 31, 2026, was ₹10.26, compared to ₹10.87 in the previous year. The company stated that EPS calculations were adjusted for a bonus issue of shares in the ratio of 10:1 during FY 2024-25 and a fresh issue of shares following its Initial Public Offering (IPO). The IPO, comprising 21,50,000 equity shares, was listed on the SME Emerge Platform of NSE Limited on November 14, 2025.
Strategic Developments
During the half year ended March 31, 2026, the company agreed to make a strategic investment in Uninova Lifesciences Private Limited by acquiring 51% of the share capital. Curis Lifesciences has already provided ₹20.655 lakh to promoters for this acquisition. Uninova Lifesciences Private Limited will become a subsidiary upon formalization of the share agreement.
Financial Position
The company’s total assets as of March 31, 2026, stood at ₹8152.07 lakh, up from ₹4259.52 lakh in the previous year. Shareholders' funds increased to ₹4735.77 lakh, driven by a rise in share capital to ₹808.44 lakh and reserves and surplus to ₹3927.33 lakh. Cash and cash equivalents improved significantly to ₹316.51 lakh from ₹30.36 lakh.
| Metric | FY26 (₹ in Lakhs) | FY25 (₹ in Lakhs) |
|---|---|---|
| Revenue from Operations | 6062.88 | 5025.86 |
| Net Profit | 691.63 | 620.64 |
| Total Income | 6091.04 | 5027.08 |
| Total Expenses | 5133.41 | 4129.52 |
| Profit Before Tax | 956.16 | 898.80 |
| Earnings Per Share (Basic) | 10.26 | 10.87 |
Historical Stock Returns for Curis Lifesciences
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -3.50% | -10.66% | -12.73% | -13.35% | -22.70% | -22.70% |
How will the strategic acquisition of Uninova Lifesciences impact Curis's revenue diversification and product pipeline in the coming fiscal year?
What are the management's capital allocation plans for the significant increase in cash reserves following the IPO?
Will the rise in total expenses outpace revenue growth in the future, or does the company expect to improve operating margins?
19
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
